Vinblastine-ifosfamide-cisplatin treatment of bulky seminoma
نویسندگان
چکیده
منابع مشابه
Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.
PURPOSE We retrospectively assessed the treatment results of patients with testicular non-seminoma to evaluate possible predictive and prognostic factors. METHODS 189 patients with testicular non-seminoma treated between 2000 and 2012 were retrospectively evaluated. Treatment was based on orchiectomy plus chemotherapy (bleomycin/etoposide/cisplatin and vinblastine/ifosfamide/ cisplatin); retr...
متن کاملTreatment of ifosfamide encephalopathy with intravenous thiamin.
Encephalopathy is a well-known side effect of IFOS. This syndrome develops in 10% of patients exposed to the drug and usually disappears after stopping therapy, although some patients may die without recovery (1). It has been proposed that IFOS metabolites may interfere with the function of flavoproteins, leading to the observed CNS disturbances (2), and therapy with methylene blue has been suc...
متن کاملSingle-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
The treatment of Ewing sarcoma (ES) in adult patients requires a multidisciplinary approach. Systemic therapy remains an important component of clinical management of this disease. ES is extremely rare in adult patients. Due to the rarity of the disease, no standard of care in terms of chemotherapy for the adult population exists, and the level of evidence for individual agents or some multidru...
متن کاملA phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
BACKGROUND Phase III studies suggest that non-small-cell lung cancer (NSCLC) patients treated with cisplatin-docetaxel may have higher response rates and better survival compared with other platinum-based regimens. We report the final results of a randomised phase III study of docetaxel and carboplatin versus MIC or MVP in patients with advanced NSCLC. PATIENTS AND METHODS Patients with biops...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 1986
ISSN: 0008-543X,1097-0142
DOI: 10.1002/1097-0142(19861115)58:10<2203::aid-cncr2820581007>3.0.co;2-s